In Vivo Model Systems for Hepatitis B Virus Research

ACS Infect Dis. 2019 May 10;5(5):688-702. doi: 10.1021/acsinfecdis.8b00223. Epub 2019 Jan 8.


Hepatitis B virus (HBV) affects more than 257 million people globally, resulting in progressively worsening liver disease, manifesting as fibrosis, cirrhosis, and hepatocellular carcinoma. The exceptionally narrow species tropism of HBV restricts its natural hosts to humans and non-human primates, including chimpanzees, gorillas, gibbons, and orangutans. The unavailability of completely immunocompetent small-animal models has contributed to the lack of curative therapeutic interventions. Even though surrogates allow the study of closely related viruses, their host genetic backgrounds, immune responses, and molecular virology differ from those of HBV. Various different models, based on either pure murine or xenotransplantation systems, have been introduced over the past years, often making the choice of the optimal model for any given question challenging. Here, we offer a concise review of in vivo model systems employed to study HBV infection and steps in the HBV life cycle or pathogenesis.

Keywords: animal model; hepatitis B virus; in vivo.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Disease Models, Animal*
  • Hepatitis B / immunology
  • Hepatitis B / virology*
  • Hepatitis B virus / immunology
  • Hepatitis B virus / pathogenicity*
  • Humans
  • Mice